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Abstract
Background Antipsychotics are commonly used to manage
behavioral and psychological symptoms of dementia.
Concerns over their safety and efficacy in this role have
resulted in antipsychotics typically being recommended for
short-term usage only when used among dementia patients.
However, there is little work examining the duration of
antipsychotic treatment in the elderly dementia patient
population.
Objective To determine the persistence of use of antipsy-
chotics in elderly dementia patients and the role of dose on
therapy duration.
Methods A retrospective, population-based cohort study
using administrative data, including dispensing records
from a provincial public drug program, from Ontario,
Canada between 2009 and 2012. Elderly dementia patients
newly initiated onto antipsychotics were followed until
drug discontinuation, death, 2-year follow-up, or end of
study. Competing risk analysis was performed to determine
time to discontinuation, stratified by categories of initial
dose.
Results After 2 years 49.1 % of the cohort (N = 22,927 of
46,695) had discontinued treatment. When stratified by
dose, the high-dose group (51.1 % discontinued) discon-
tinued more frequently than the medium- (48.7 % discon-
tinued) and low- (47.5 % discontinued) dose groups
(p\ 0.0001).
Conclusion Approximately half of elderly dementia
patients treated with antipsychotics discontinue within
2 years, with those on higher doses more likely to dis-
continue. However, the number of patients remaining on
therapy represents a serious public health concern.
Key Points
Antipsychotics are often used to manage the
behavioral and psychological symptoms of dementia,
although safety and efficacy concerns generally
warrant only short-term usage of these medications.
Just over half of elderly dementia patients treated
with antipsychotics in Ontario, Canada, were
persistent to drug treatment during the 2-year study
period.
Patients initiated on a higher initial dose of
antipsychotic appeared to discontinue more
frequently than those treated with lower doses.
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1 Introduction
Antipsychotics represent a drug class that has garnered a
large amount of both clinical and public interest in its role
in treating a number of mental health conditions, particu-
larly with regard to the elderly. These drugs have been used
for many years to treat psychosis-associated conditions
such as schizophrenia and bipolar disorder; however, they
are also used extensively to treat behavioral and psycho-
logical symptoms of dementia (BPSD) [1, 2]. As antipsy-
chotics have been increasingly used to treat BPSD, their
safety and efficacy has come under question. It is now well
documented that the use of antipsychotics among the
elderly, particularly those with dementia, results in
increased morbidity and mortality [2–6]. Specifically,
observational studies using administrative databases have
demonstrated increased risk of cardiovascular death, heart
failure, and sudden death, as well as a heightened risk for
falls and fractures amongst elderly patients with dementia
taking both typical and atypical antipsychotics [1, 4, 5, 7].
This body of work has prompted governmental agencies,
including the US Food and Drug Administration (FDA)
and Health Canada, to advise against the use of antipsy-
chotics in those with dementia, except for treating only the
most severe behavioral and psychological symptoms of
dementia [8, 9].
With the widespread use of antipsychotics and the var-
ious different drugs and formulations available, a deeper
understanding of dose prescribed and duration of therapy
among the elderly is important to explore. Among patients
with schizophrenia and bipolar disorder, where antipsy-
chotic use is indicated, studies have shown low rates of
adherence to both typical and atypical antipsychotics [10–
14]. While the nature of these conditions may contribute to
discontinuation, adverse effects of the drugs also appear to
play a vital role in discontinuation of treatment [10–13].
Furthermore, many clinical practice guidelines recommend
short-duration treatment with antipsychotics among
dementia patients, recommending 3–6 months before dis-
continuing, with frequent monitoring to assess safety and
efficacy [15].
Persistence to antipsychotic therapy has been explored
in increasing detail among schizophrenia and other psy-
chosis-associated patients, though there is little informa-
tion regarding persistence rates in elderly patients with
dementia, who differ from the other patients as a short
duration of antipsychotic use is recommended. We
examined elderly patients with dementia to identify
trends in their persistence to antipsychotic therapy, and




We conducted a population-based, retrospective cohort
study among patients with dementia aged 66 years or older
residing in Ontario, Canada, and who were initiated on
treatment with an antipsychotic between 1 January 2009
and 31 December 2012. This study was approved by the
Research Ethics Board of Sunnybrook Health Sciences
Centre, Toronto, ON, Canada.
2.2 Data Sources
We used linked administrative healthcare databases for
cohort identification, co-morbidity assessment, and out-
come ascertainment. We used the Ontario Drug Benefit
(ODB) database, a computerized pharmacy records system
that records prescription drugs dispensed to all Ontario
residents over 65 years of age to obtain prescription data.
The Canadian Institute for Health Information Discharge
Abstract Database (CIHI-DAD) was used to obtain records
of inpatient hospitalizations, including diagnostic and
procedural information, while the CIHI National Ambula-
tory Care Reporting System (CIHI-NACRS) was used to
obtain details of emergency department visits. Further-
more, the CIHI Ontario Mental Health Reporting System
(CIHI-OMHRS) was used to obtain information about
mental health diagnoses. Physician billing information and
demographic information were obtained from the Ontario
Health Insurance Plan (OHIP) database and the Ontario
Registered Persons Database (RPDB), respectively. Data
from the OHIP database was coupled with the ICES
Physician Database (IPDB) to identify the specialty of
antipsychotic prescribers. These datasets were linked using
unique, encoded identifiers and analyzed at the Institute for
Clinical Evaluative Sciences (ICES).
2.3 Cohort Definition
We identified users of antipsychotics based upon pre-
scription records for any atypical or typical antipsychotic
within the accrual period (January 2009 to December
2012). We defined the date of each patient’s first pre-
scription as their cohort entry date and restricted the cohort
to patients with dementia by means of a validated dementia
definition, based on a hospitalization or physician visit with
a dementia diagnosis in the previous 5 years (using OHIP
or CIHI-DAD diagnostic codes) or a cognitive enhancer
prescription dispensed in the year prior [16]. We excluded
patients less than 66 years old at cohort entry and those
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who were prescribed any antipsychotic in the year prior to
the cohort entry date in order to restrict the cohort to
elderly individuals newly initiated on antipsychotic treat-
ment. Finally, individuals were excluded if they were only
dispensed one prescription, as it is highly likely that these
individuals never initiated therapy. This is an approach
used regularly in research leveraging administrative claims
databases investigating medication persistence [17, 18].
2.4 Duration of Exposure
Patients were followed forward from the date of their first
prescription until they discontinued therapy, died, had
2 years of follow-up, or reached the end of the study period
(31 December 2013). For each patient, a period of con-
tinuous drug use was defined as receipt of a subsequent
prescription refill within 180 days of the previous pre-
scription in order to account for varied prescription regimes
and minor lapses in treatment. Patients who switched
between different antipsychotics were still considered to be
persistent. In a sensitivity analyses, we used an alternate,
stricter definition for continuous use, whereby an individ-
ual was persistent if a prescription refill was identified
within 1.5 times the days supplied of the previous
prescription.
2.5 Statistical Analyses
We summarized the baseline characteristics of all indi-
viduals included in the study, including demographic
information and a variety of relevant clinical characteris-
tics. We also examined the prevalence of schizophrenia
and bipolar co-diagnoses among patients in our cohort by
looking for relevant diagnostic codes from CIHI-OMHRS
and OHIP databases [19]. We conducted a competing risk
analysis to determine time to discontinuation of any
antipsychotic, accounting for death as a competing risk as a
potentially high mortality rate was hypothesized for our
cohort. We reported all analyses overall and stratified by
the antipsychotic dose initiated to observe the effect of
dosage on persistence. Doses were divided into three cat-
egories defined using tertiles of the dose initiated—low
dose (\26 mg/day), medium dose (26–74 mg/day), and
high dose ([74 mg/day)—normalized into milligrams of
chlorpromazine equivalent dose [20]. Standardized differ-
ences were calculated to compare the characteristics of the
low- and medium-dose groups against the high dose group,
with significance achieved if the standardized difference
was greater than 0.1 [21]. Gray’s test was used to check for
the significance of any differences in the time to discon-
tinuation between dose groups in the competing risk
analysis [22]. All analyses were conducted using SAS
Enterprise Guide (version 6.1, Cary, NC, USA).
3 Results
3.1 Patient Characteristics
Over the study period, we identified 60,594 elderly indi-
viduals with dementia who were newly initiated onto
antipsychotic treatment, among whom 46,695 individuals
were dispensed more than one antipsychotic prescription
and so were eligible for the study. Of those eligible, 16,563
(35.5 %) initiated therapy on low–dose, 14,266 (30.6 %)
initiated therapy on medium–dose, and 15,866 (34.0 %)
initiated therapy on high–dose antipsychotic therapy. The
median age for the new patients beginning treatment was
84 years (interquartile range 78–88), and 29,064 (62.2 %)
of the patients were women. We found that overall only
1.6 % of individuals had a co-diagnosis of schizophrenia,
and 0.8 % had a co-diagnosis of bipolar disorder. The
patient characteristics are shown in Table 1, while the
number of patients initiated on specific antipsychotics is
shown in Table 2.
3.2 Primary Analyses
Of the 46,695 elderly patients with dementia who newly
initiated antipsychotic therapy, 24.4 % discontinued
therapy after 6 months and 35.1 % discontinued therapy
after 1 year. By the end of the 2-year study period,
49.1 % of patients in the cohort had discontinued
antipsychotic therapy. Furthermore, we observed that
18.4 % of patients had died by the end of the study. The
results from the competing risk analysis are shown in
Fig. 1.
When we stratified by the initial dose, we found that
after a 1-year follow-up, 32.3 % of low-dose patients,
34.1 % of medium-dose patients, and 39.0 % of high-
dose patients had discontinued antipsychotic therapy.
Similarly, by the end of the study period, 47.5 % of low-
dose patients, 48.7 % of medium-dose patients, and
51.1 % of high-dose patients had discontinued antipsy-
chotic therapy, while 17.0 % of low-dose patients,
17.6 % of medium-dose patients, and 20.7 % of high-
dose patients had died (Fig. 2). The difference in time to
discontinuation across the dose levels was found to be
significant in our primary analysis (p\ 0.0001). In our
sensitivity analysis using the stricter definition of con-
tinuous use, the results were consistent (p\ 0.0001). The
mean duration of follow-up for all individuals in the
cohort was 393 days [standard deviation (SD) 273 days]
.The mean duration of antipsychotic use among those
starting on a low dose was 258 days (SD 203 days),
compared with 246 days (SD 200 days) and 213 days
(SD 193 days) among those initiating medium- and high-
dose therapy, respectively.
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Table 1 Baseline characteristics of elderly dementia patients newly initiated on antipsychotic treatments
Overall
N = 46,695








Median (IQR) 84 (78–88) 84 (79–89)* 84 (78–88)* 83 (77–88)
Male (%) 17,631 (37.8 %) 5843 (35.3 %)* 5296 (37.1 %) 6492 (40.9 %)
Location of residence
Missing 67 (0.1 %) 16 (0.1 %) 23 (0.2 %) 28 (0.2 %)
Urban 40,295 (86.3 %) 14,637 (88.4 %)* 12,336 (86.5 %) 13,322 (84.0 %)
Rural 6333 (13.6 %) 1910 (11.5 %)* 1907 (13.4 %) 2516 (15.9 %)
Number of unique medications (based on drug name) in last year
Median (IQR) 11 (7–15) 11 (7–15) 11 (7–15) 10 (6–15)
Hospitalizations within the last year
Number with one or more hospitalizations 17,601 (37.7 %) 5745 (34.7 %)* 5097 (35.7 %)* 6759 (42.6 %)
Emergency visits within the last year
0 15,442 (33.1 %) 6093 (36.8 %)* 5036 (35.3 %)* 4313 (27.2 %)
1 12,814 (27.4 %) 4453 (26.9 %) 3862 (27.1 %) 4499 (28.4 %)
2–4 14,656 (31.4 %) 4818 (29.1 %)* 4261 (29.9 %)* 5577 (35.2 %)
5? 3783 (8.1 %) 1199 (7.2 %) 1107 (7.8 %) 1477 (9.3 %)
Physician office visits within the last year
Median (IQR) 3 (2–5) 3 (1–5) 3 (1–5) 3 (2–5)
Specialist visits within 3 months
Psychiatrists 8205 (17.6 %) 2542 (15.3 %)* 2378 (16.7 %)* 3285 (20.7 %)
Neurologists 3543 (7.6 %) 1386 (8.4 %) 995 (7.0 %) 1162 (7.3 %)
Geriatrician 7340 (15.7 %) 2584 (15.6 %) 2301 (16.1 %) 2455 (15.5 %)
Charlson morbidity index
No hospitalization 20,597 (44.1 %) 7758 (46.8 %)* 6543 (45.9 %)* 6296 (39.7 %)
0 5773 (12.4 %) 2102 (12.7 %) 1736 (12.2 %) 1935 (12.2 %)
1 7854 (16.8 %) 2655 (16.0 %) 2351 (16.5 %) 2848 (18.0 %)
2 4816 (10.3 %) 1668 (10.1 %) 1447 (10.1 %) 1701 (10.7 %)
3? 7655 (16.4 %) 2380 (14.4 %)* 2189 (15.3 %)* 3086 (19.5 %)
Concomitant psychotropic use during continuous use of antipsychotic
Antidepressants 31,243 (66.9 %) 11,024 (66.6 %) 9716 (68.1 %) 10,503 (66.2 %)
Benzodiazepine 18,711 (40.1 %) 6200 (37.4 %)* 5614 (39.4 %) 6897 (43.5 %)
Mood stabilizer 3913 (8.4 %) 1262 (7.6 %) 1152 (8.1 %) 1499 (9.4 %)
Stimulants 178 (0.4 %) 47 (0.3 %) 59 (0.4 %) 72 (0.5 %)
Cognitive enhancers 22,797 (48.8 %) 8706 (52.6 %)* 7268 (50.9 %)* 6823 (43.0 %)
Prescriber of initial antipsychotic prescriptions
Missing 1192 (2.6 %) 439 (2.7 %) 319 (2.2 %) 434 (2.7 %)
Other 8048 (17.2 %) 3025 (18.2 %)* 2525 (17.7 %)* 2498 (15.8 %)
General practitioner 37,461 (80.2 %) 13,103 (79.1 %) 11,424 (80.1 %) 12,934 (81.5 %)
Equivalent daily doses of antipsychotic dispensed
Mean (SD) 106.69 ± 213.38 18.07 ± 6.08* 45.79 ± 9.74* 253.96 ± 317.26
Median (IQR) 46 (20–100) 20 (11–23)* 50 (40–50)* 150 (100–287)
Psychosis co-diagnosis
Schizophrenia 740 (1.6 %) 153 (0.9 %)* 160 (1.1 %)* 427 (2.7 %)
Bipolar disorder 395 (0.8 %) 73 (0.4 %)* 99 (0.7 %) 223 (1.4 %)
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4 Discussion
In this population-based study, we found that just over half
of elderly dementia patients treated with antipsychotics
were persistent to therapy over our 2-year study period.
Furthermore, we found that persistence to antipsychotic
therapy was lower when patients were initiated on higher












Schizophrenia or bipolar disorder 1064 (2.3 %) 214 (1.3 %)* 248 (1.7 %)* 602 (3.8 %)
SD standard deviation, IQR interquartile range
* Denotes significant difference (p\ 0.05) when compared to other equivalent daily dosing groups
Table 2 Antipsychotic drug groups stratified by initial equivalent daily dose of chlorpromazine
Antipsychotic drug group Total
N = 46,695







Aripiprazole 184 (0.4 %) 25 (0.2 %) 110 (0.8 %) 49 (0.3 %)
Chlorpromazine 114 (0.2 %) 31 (0.2 %) 24 (0.2 %) 59 (0.4 %)
Haloperidol 2581 (5.5 %) 104 (0.6 %) 746 (5.2 %) 1731 (10.9 %)
Loxapine 107 (0.2 %) 12 (0.1 %) 29 (0.2 %) 66 (0.4 %)
Methotrimeprazine 328 (0.7 %) 109 (0.7 %) 104 (0.7 %) 115 (0.7 %)
Olanzapine 4937 (10.6 %) 58 (0.4 %) 349 (2.4 %) 4530 (28.6 %)
Quetiapine 18,902 (40.5 %) 10,922 (65.9 %) 6156 (43.2 %) 1824 (11.5 %)
Risperidone 16,023 (34.3 %) 5246 (31.7 %) 6297 (44.1 %) 4480 (28.2 %)
Other antipsychotic 1647 (3.5 %) 54 (0.3 %) 352 (2.5 %) 1241 (7.8 %)





















Fig. 1 Proportion of cohort (N = 46,695) of elderly dementia
patients newly initiated on antipsychotic treatment that discontinued

























Fig. 2 Proportion of cohort (N = 46,695) of elderly dementia
patients newly initiated on antipsychotic treatment that discontinued
treatment or died during the 2-year study period, stratified by initial
antipsychotic dose. Dose divisions of low (\26 mg/day), medium
(26–74 mg/day), and high ([74 mg/day) were determined from
tertiles of initial doses and are given in chlorpromazine equivalent
daily doses
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These findings are similar to those identified in other
studies examining the persistence and adherence of
antipsychotics among schizophrenia and bipolar patients, and
are also similar to those observed among some other chronic
medications used in the elderly such as statins [10, 14, 23]. In
a study by Valenstein et al. [10] examining the adherence to
antipsychotics among schizophrenia patients, 40 % of
patients were found to be poorly adherent to therapy, while a
study by Sajatovic et al. [14] of antipsychotic adherence
among bipolar patients found 48.1 % of individuals were
either partially adherent or non-adherent. These discontinu-
ations are generally attributed in part to the serious side
effects associated with antipsychotic treatment, and whether
these trends are found amongst the elderly dementia patient
population is a question for future studies [24].
When using antipsychotics to treat schizophrenia and
bipolar patients, clinicians aim to encourage medication
adherence, while in managing BPSD, clinical practice
guidelines and governmental advisories favor short-term
use of antipsychotics due to the potential serious harm of
these products in this population [8, 9, 15]. Therefore our
finding that the majority of patients were persistent to their
treatments over the 2-year study period is concerning. With
the widespread use of antipsychotics among the elderly
dementia patient population, this finding raises questions
about why so many patients were kept on antipsychotic
therapy well beyond recommended durations, and high-
lights the need for further research on antipsychotic treat-
ments in this population. Furthermore, it is additionally
concerning that just over 40 % of the cohort was con-
comitantly being treated with benzodiazepines, given the
dangers associated with their use among the elderly and
frail and their possible association with dementia and
cognitive decline [25–27]. The risk of falls and fractures as
well as more serious adverse events is likely to be
heightened amongst the individuals in our study due to
their treatment with both antipsychotics and benzodi-
azepines, and thus is a troubling finding from our study that
should not be overlooked by clinicians.
Our study also demonstrates the potential relationship
between persistence and initial dose of antipsychotic
administered. We found that over a third of the cohort
began treatment on a high dose of antipsychotic, which is
concerning as the general approach to BPSD with
antipsychotics is to initiate on low doses and slowly
increase over time [15]. We also found that there was a
small but significant difference between persistence pat-
terns by dose groupings, with more frequent discontinua-
tions among those initiating higher doses. It is possible that
those on higher doses experienced greater side effects
while on treatment and this prompted discontinuation,
although our current study was not able to assess the reason
for treatment discontinuation.
However, one must also consider the possibility that
clinicians that are prescribing the higher-dose antipsy-
chotics are aware of the safety risks associated with the
medication use and thus are discontinuing treatment more
rapidly than in patients initiated on lower doses. We
believe that this possibility bears further consideration, and
presents itself as a future avenue for research. It is also
possible that patient differences between the dose groups
could explain this finding. Our comparison of the charac-
teristics of antipsychotic users between dose groups
(Table 1) shows that these patients differ on a number of
characteristics, including age, concomitant cognitive
enhancer use, and psychiatrist visits within the past
3 months. While the differences seen were statistically
significant, the relative differences between the character-
istics of the groups were generally fairly small, suggesting
that the patient populations were overall fairly similar.
An important point to consider with regard to medication
persistence among the dementia patient population is the
variation in the ability to self-manage treatments and the
patient’s capacities tomakedecisions.Themajority of patients
with dementiamay have some impairment that can affect their
ability to receive treatment, with a worsening of these
impairments as the disease progresses [28]. This often results
in family members or other caregivers becoming responsible
for the medication management of dementia patients, with
physicians often advised to take more active monitoring roles
[29]. This also further highlights the need to explore why
patients were maintained on therapy, as physicians are often
muchmore active in patient medicationmanagement [15, 29].
Some limitations of this study do bear consideration. We
were unable to determine the reason for discontinuation of
antipsychotic therapy in our study and can thus only specu-
late on the role of side effects. As such this presents itself as a
future avenue for further research, particularly if awareness
amongst clinicians of the side effects prompted the discon-
tinuations as mentioned earlier. One other limitation of this
study is that it used only the prescription records for patients,
and therefore there is no way to ensure that patients were in
fact taking the medication that they were prescribed. How-
ever, by restricting our population to those individuals who
were dispensed more than one prescription, we have
increased the likelihood that there were active users of these
medications. Furthermore, we were not able to identify
whether discontinuation was driven by the initial dose given
or rather by the maximum dose given to patients.
5 Conclusions
Our study demonstrates a high level of persistence to
antipsychotic therapy among elderly dementia patients
over a 2-year period, despite recommendations against the
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long-term use of these drugs for these patients. Further-
more, our findings show that higher doses of these drugs
may be associated with more frequent discontinuations,
possibly due to the role of side effects. Our findings
highlight the need for further research into the usage and
duration of antipsychotic therapy among the elderly, par-
ticularly due to the potential serious side effects associated
with use of these medications.
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